Literature DB >> 15496415

Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function.

Koji Ikeda1, Thomas Quertermous.   

Abstract

Cell adhesion molecules regulate a variety of endothelial cell functions such as migration, response to inflammation, and angiogenesis. Recently, activated leukocyte cell adhesion molecule (ALCAM), a member of the Ig superfamily, has been detected in the primitive subsets of hematopoietic cells and endothelial cells during embryogenesis. ALCAM supports the development of hematopoietic cells as well as enhancing capillary tube formation in vitro. Here, we isolated a novel soluble isoform of ALCAM (sALCAM) that is produced via alternative splicing. sALCAM contains the single amino-terminal Ig-like domain of ALCAM and lacks a transmembrane domain. When expressed in cultured cells, sALCAM was properly secreted into the media. Both ALCAM and sALCAM are expressed in a variety of cultured human endothelial cells. Notably, their transcripts were differentially regulated in human microvascular endothelial cells (HMVEC) upon tumor necrosis factor-alpha stimulation. ALCAM significantly enhanced tube formation of endothelial-like yolk sac cells on Matrigel, whereas it inhibited their migration in vitro. sALCAM completely abolished these effects of ALCAM. Furthermore, sALCAM enhanced migration of mock-transfected endothelial-like yolk sac cells that do not express ALCAM, indicating that sALCAM has an independent effect on cell migration in addition to modulating ALCAM function. In addition, sALCAM significantly enhanced migration of HMVEC, whereas it inhibited tube formation of HMVEC on Matrigel. sALCAM demonstrated an ability to bind ALCAM and partially inhibited ALCAM-ALCAM homophilic interactions. Taken together, these data characterize a novel soluble isoform of ALCAM that may have ALCAM-dependent and ALCAM-independent functions, providing further insights regarding the role of this adhesion molecule in the regulation of endothelial cell function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496415     DOI: 10.1074/jbc.M407776200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion.

Authors:  Noriyuki Kijima; Naoki Hosen; Naoki Kagawa; Naoya Hashimoto; Akiko Nakano; Yasunori Fujimoto; Manabu Kinoshita; Haruo Sugiyama; Toshiki Yoshimine
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis.

Authors:  Syed M A Abidi; Mohammad K Saifullah; Marie D Zafiropulos; Cara Kaput; Michael A Bowen; Calvin Cotton; Nora G Singer
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

Review 3.  Intercellular adhesion molecules (ICAMs) and spermatogenesis.

Authors:  Xiang Xiao; Dolores D Mruk; C Yan Cheng
Journal:  Hum Reprod Update       Date:  2013-01-03       Impact factor: 15.610

4.  Side-specific expression of activated leukocyte adhesion molecule (ALCAM; CD166) in pathosusceptible regions of swine aortic valve endothelium.

Authors:  Marie A Guerraty; Gregory R Grant; John W Karanian; Oscar A Chiesa; William F Pritchard; Peter F Davies
Journal:  J Heart Valve Dis       Date:  2011-03

5.  ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9.

Authors:  Alvaro Gilsanz; Lorena Sánchez-Martín; María Dolores Gutiérrez-López; Susana Ovalle; Yesenia Machado-Pineda; Raquel Reyes; Guido W Swart; Carl G Figdor; Esther M Lafuente; Carlos Cabañas
Journal:  Cell Mol Life Sci       Date:  2012-09-30       Impact factor: 9.261

6.  Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

Authors:  Shingo Inaguma; Jerzy Lasota; Zengfeng Wang; Piotr Czapiewski; Renata Langfort; Janusz Rys; Joanna Szpor; Piotr Waloszczyk; Krzysztof Okoń; Wojciech Biernat; Hiroshi Ikeda; David S Schrump; Raffit Hassan; Markku Miettinen
Journal:  Hum Pathol       Date:  2017-08-12       Impact factor: 3.466

7.  JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.

Authors:  Dionna W Williams; Kathryn Anastos; Susan Morgello; Joan W Berman
Journal:  J Leukoc Biol       Date:  2014-11-24       Impact factor: 4.962

8.  ALCAM: Basis Sequence: Mouse.

Authors:  Amanda G Hansen; Guido W Swart; Andries Zijlstra
Journal:  AFCS Nat Mol Pages       Date:  2011

9.  Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells.

Authors:  Virginia Dippel; Karin Milde-Langosch; Daniel Wicklein; Udo Schumacher; Peter Altevogt; Leticia Oliveira-Ferrer; Fritz Jänicke; Christine Schröder
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-16       Impact factor: 4.553

10.  CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity.

Authors:  Rüdiger von Bauer; Dimitrios Oikonomou; Alba Sulaj; Sawsan Mohammed; Agnes Hotz-Wagenblatt; Hermann-Josef Gröne; Bernd Arnold; Christine Falk; Dorit Luethje; Axel Erhardt; David M Stern; Angelika Bierhaus; Peter P Nawroth
Journal:  J Immunol       Date:  2013-05-31       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.